Thomson Kenneth S, AbdelGhani Sameh, Snyder James W, Thomson Gina K
Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt.
Antibiotics (Basel). 2019 Mar 23;8(1):32. doi: 10.3390/antibiotics8010032.
This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP⁻ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of , , and . Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data.
本研究比较了头孢吡肟+西他巴坦（FEP-ZID）与目前选用的几种抗菌药物对一组耐多药（MDR）临床分离菌株的活性，这些菌株被选来对抗菌活性构成极大挑战。FEP-ZID具有非常广泛且强效的体外活性谱，对许多MDR的大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌分离株具有高度活性。值得注意的是，它能抑制产生安布勒A、B和D类碳青霉烯酶的分离株，以及具有多种耐药机制的分离株，这些机制包括上调的外排、减少或无功能的OprD孔蛋白以及AmpC过度产生。其临床作用最初将由赋予它的断点、与其他研究性β-内酰胺酶抑制剂组合的比较研究来确定，最终将由不断发展的治疗结果数据来确定。
